Clinical Trial Update: Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the combination of icotinib and arsenic trioxide for non-small cell lung cancer with resistance to EGFR-TKI therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: UNKNOWN